Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cerus CorporationNASDAQ: CERS

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 194.14M shares rose 3.8% year over year, in line with the +3.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.8% holds above the trailing-twelve-month pace of +3.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
194.14M+1.1% QoQ
Last fiscal yearDec 2025
190.59M+3.3% YoY
LTMMar 2026
192.35M+3.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.8%——
1 year+3.3%——
3-year CAGR+2.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
190.59M USD
Year-over-year change
+3.3%
4-year CAGR
+2.7%

Weighted Avg Shares (Diluted) vs competitors

How CERS compares with its peers on the latest reported figures

  • CERS's LTM Mar 2026 weighted avg shares (diluted) of 192.35M shares is the 3rd highest of the 4 companies compared; the peer median is 239.7M shares.
  • Its year-over-year change of +3.7% is the highest of 4, against a peer median of -2.6%.
  • Over three fiscal years its annual growth of +2.6% compares with a peer median of +0.0%.
CERS Competitors Peer median
Weighted Avg Shares (Diluted) for CERS and competitors
Company Period LTM YoY 3-year CAGR
GRFSGrifols, S.A.LTM Jun 2026680.56M -0.2%+0.0%
ADMAADMA Biologics, Inc.LTM Jun 2026239.7M -2.6%+7.4%
CERSCerus CorporationLTM Mar 2026192.35M +3.7%+2.6%
HAEHaemonetics CorporationLTM Jun 202646.64M -6.6%-2.7%
Peer median (excluding CERS) 239.7M-2.6%+0.0%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.86M162.05M156.37M180.27M206.13M
Cost of Revenue63.48M74.95M69.97M80.75M95.85M
Gross Profit67.38M87.09M86.4M99.52M110.29M
Gross Margin51.5%53.7%55.3%55.2%53.5%
Research & Development63.69M64.11M67.64M58.91M65.72M
Selling, General & Admin81.29M83.34M75.52M75.89M80.91M
Operating Expenses116.32M121.18M116.45M113.75M146.63M
Depreciation & Amortization3.15M2.98M2.6M1.86M2M
EBITDA(45.99M)(33.52M)(26.34M)(10.02M)(4.94M)
EBITDA Margin-35.1%-20.7%-16.8%-5.6%-2.4%
Operating Income(48.94M)(34.08M)(30.05M)(14.23M)(36.35M)
Operating Margin-37.4%-21.0%-19.2%-7.9%-17.6%
Interest Income00000
Interest Expense4.92M5.83M8.39M8.88M8.34M
Other Income / Expenses(5.12M)(8.26M)(7.27M)(6.53M)21.06M
Income Before Tax(54.06M)(42.34M)(37.32M)(20.76M)(15.28M)
Pre-Tax Margin-41.3%-26.1%-23.9%-11.5%-7.4%
Income Tax Expense319K488K325K205K354K
Net Income(54.37M)(42.78M)(37.49M)(20.92M)(15.63M)
Net Margin-41.6%-26.4%-24.0%-11.6%-7.6%
EPS (Basic)(0.32)(0.24)(0.21)(0.11)(0.08)
EPS (Diluted)(0.32)(0.24)(0.21)(0.11)(0.08)
Weighted Avg Shares171.28M176.55M180.27M184.56M190.59M
Weighted Avg Shares (Diluted)171.28M176.55M180.27M184.56M190.59M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.